An Open-label, Single Centre Relative Bioavailability Study With an Adaptive Design Comparing up to 5 Solid Oral AZD5069 Formulations After Single Dose Administration to Healthy Volunteers
Latest Information Update: 09 May 2019
At a glance
- Drugs AZD 5069 (Primary)
- Indications Asthma; Bronchiectasis; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 31 May 2018 Results summarizing the PK profile of AZD5069 from eight phase 1 studies (NCT00953888, NCT01051505, NCT01083238, NCT01100047, NCT01332903, NCT01480739, NCT01735240, NCT01989520; n=240) published in the Drugs in R and D
- 25 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Nov 2013 New trial record